Of note, PDAC therapy could further benefit from combination of small-molecule ULK1/2 kinase inhibitor and 2-DG or 3-BP, supporting investigation of autophagy blockade in combination with the two anti-cancer agents as a promising therapeutic approach in clinical trials of PDAC patients. This evidence concerns the gene ULK1 and cancer.